JP6539268B2 - 慢性潰瘍の新規治療 - Google Patents

慢性潰瘍の新規治療 Download PDF

Info

Publication number
JP6539268B2
JP6539268B2 JP2016532032A JP2016532032A JP6539268B2 JP 6539268 B2 JP6539268 B2 JP 6539268B2 JP 2016532032 A JP2016532032 A JP 2016532032A JP 2016532032 A JP2016532032 A JP 2016532032A JP 6539268 B2 JP6539268 B2 JP 6539268B2
Authority
JP
Japan
Prior art keywords
wound
dose
per
aqueous pharmaceutical
treatment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
JP2016532032A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016537373A (ja
Inventor
アルヴァー・グレンバリ
クリスティーネ・ディーテリッヒ
マルギット・マフラフォー
Original Assignee
プロモア・ファーマ・アクチエボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プロモア・ファーマ・アクチエボラーグ filed Critical プロモア・ファーマ・アクチエボラーグ
Publication of JP2016537373A publication Critical patent/JP2016537373A/ja
Application granted granted Critical
Publication of JP6539268B2 publication Critical patent/JP6539268B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1729—Cationic antimicrobial peptides, e.g. defensins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
    • A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
    • A61L15/42—Use of materials characterised by their function or physical properties
    • A61L15/44—Medicaments
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
    • A61L26/0019—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
    • A61L26/0061—Use of materials characterised by their function or physical properties
    • A61L26/0085—Porous materials, e.g. foams or sponges
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/252—Polypeptides, proteins, e.g. glycoproteins, lipoproteins, cytokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/404—Biocides, antimicrobial agents, antiseptic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Materials Engineering (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Materials For Medical Uses (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Saccharide Compounds (AREA)
JP2016532032A 2013-11-19 2014-11-19 慢性潰瘍の新規治療 Expired - Fee Related JP6539268B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBPCT/GB2013/053053 2013-11-19
PCT/GB2013/053053 WO2015075406A1 (en) 2013-11-19 2013-11-19 New treatment of chronic ulcers
PCT/GB2014/053415 WO2015075441A1 (en) 2013-11-19 2014-11-19 New treatment of chronic ulcers

Publications (2)

Publication Number Publication Date
JP2016537373A JP2016537373A (ja) 2016-12-01
JP6539268B2 true JP6539268B2 (ja) 2019-07-03

Family

ID=49998562

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2016532032A Expired - Fee Related JP6539268B2 (ja) 2013-11-19 2014-11-19 慢性潰瘍の新規治療

Country Status (15)

Country Link
US (3) US10226508B2 (enExample)
EP (1) EP3071216B1 (enExample)
JP (1) JP6539268B2 (enExample)
KR (1) KR102360938B1 (enExample)
CN (1) CN105939726A (enExample)
AU (1) AU2014351607B2 (enExample)
BR (1) BR112016011166A8 (enExample)
CA (1) CA2927557C (enExample)
ES (1) ES2925876T3 (enExample)
MX (1) MX379357B (enExample)
PL (1) PL3071216T3 (enExample)
RU (1) RU2707254C1 (enExample)
TW (1) TWI698251B (enExample)
WO (2) WO2015075406A1 (enExample)
ZA (1) ZA201604110B (enExample)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0808376D0 (en) 2008-05-08 2008-06-18 Bristol Myers Squibb Co Wound dressing
GB0817796D0 (en) 2008-09-29 2008-11-05 Convatec Inc wound dressing
GB201020236D0 (en) 2010-11-30 2011-01-12 Convatec Technologies Inc A composition for detecting biofilms on viable tissues
CN103347562B (zh) 2010-12-08 2016-08-10 康沃特克科技公司 伤口分泌液系统附件
US10207031B2 (en) 2010-12-08 2019-02-19 Convatec Technologies Inc. Integrated system for assessing wound exudates
ES2940916T3 (es) 2010-12-08 2023-05-12 Convatec Technologies Inc Sistema para eliminar exudados del sitio de una herida
GB201115182D0 (en) 2011-09-02 2011-10-19 Trio Healthcare Ltd Skin contact material
GB2497406A (en) 2011-11-29 2013-06-12 Webtec Converting Llc Dressing with a perforated binder layer
GB201120693D0 (en) 2011-12-01 2012-01-11 Convatec Technologies Inc Wound dressing for use in vacuum therapy
CN105008611A (zh) 2012-12-20 2015-10-28 康沃特克科技公司 化学改性的纤维素纤维的处理
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers
EP3288600B1 (en) 2015-04-28 2023-09-06 ConvaTec Technologies Inc. Antibacterial nanofibres
GB2543544A (en) 2015-10-21 2017-04-26 Brightwake Ltd Wound dressing
EP3436820A2 (en) 2016-03-30 2019-02-06 Qualizyme Diagnostics GmbH&Co KG Detecting microbial infection in wounds
EP3936095B1 (en) 2016-03-30 2024-06-19 ConvaTec Technologies Inc. Detecting microbial infections in wounds
GB201608099D0 (en) 2016-05-09 2016-06-22 Convatec Technologies Inc Negative pressure wound dressing
CA3030153C (en) 2016-07-08 2023-10-24 Convatec Technologies Inc. Fluid flow sensing
BR112019000284A2 (pt) 2016-07-08 2019-04-16 Convatec Technologies Inc. aparelho de coleta de fluido
WO2018009880A1 (en) 2016-07-08 2018-01-11 Convatec Technologies Inc. Flexible negative pressure system
US11795192B2 (en) 2017-03-10 2023-10-24 Lakewood Amedex, Inc. Antimicrobial compounds, compositions, and uses thereof
PT3638251T (pt) 2017-06-12 2024-05-22 Lakewood Amedex Inc Formulações de gel de bifosfocina e suas utilizações
CN111836655A (zh) 2017-11-16 2020-10-27 康沃特克有限公司 流体收集设备
US11123357B2 (en) 2018-10-17 2021-09-21 Lakewood Amedex, Inc. Methods and compositions for treating oral mucositis
JP7511585B2 (ja) 2019-06-03 2024-07-05 コンバテック リミティド 病原体を破壊して封じ込めるための方法およびデバイス
US11331221B2 (en) 2019-12-27 2022-05-17 Convatec Limited Negative pressure wound dressing
US11771819B2 (en) 2019-12-27 2023-10-03 Convatec Limited Low profile filter devices suitable for use in negative pressure wound therapy systems

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5271943A (en) * 1989-10-27 1993-12-21 Scott Health Care Wound gel compositions containing sodium chloride and method of using them
US5641483A (en) * 1995-06-07 1997-06-24 Beaulieu; Andre Wound healing formulations containing human plasma fibronectin
JP4048565B2 (ja) 1996-04-23 2008-02-20 東レ株式会社 「抗ピロリ菌剤」
US6201164B1 (en) * 1996-07-11 2001-03-13 Coloplast A/S Hydrocolloid wound gel
US6861067B2 (en) 1998-09-17 2005-03-01 Sherwood Services Ag Hydrogel wound dressing and the method of making and using the same
US6835713B2 (en) 2001-02-16 2004-12-28 University Of Pittsburgh Virus derived antimicrobial peptides
EP1358888A1 (en) 2002-02-28 2003-11-05 Robert Bals The human peptide antibiotic LL-37/hCAP-18 is an inducer of angiogenesis
SE0300207D0 (sv) 2003-01-29 2003-01-29 Karolinska Innovations Ab New use and composition
US7262179B2 (en) * 2003-05-28 2007-08-28 Bristol-Myers Squibb Company Wound care compositions
EP1621205A1 (en) * 2004-07-28 2006-02-01 OctoPlus Technologies B.V. Antimicrobial peptides derived from CAP18
ZA200600686B (en) * 2006-01-24 2006-04-26 Jacobus F Mouton A wound dressing
US20080226724A1 (en) * 2007-01-19 2008-09-18 Genentech, Inc. Prevention of hydrogel viscosity loss
US20100178320A1 (en) * 2007-06-25 2010-07-15 Lipopeptide Ab New medical products
US8529897B2 (en) * 2007-08-16 2013-09-10 Carnegie Mellon University Inflammation-regulating compositions and methods
BRPI0821814A2 (pt) * 2007-12-28 2015-06-16 Heraeus Kulzer Gmbh Uso e formulação tópica de eritropoietina para a cicatrização da pele
AU2010316006B2 (en) 2009-11-03 2013-09-26 Lipidor Ab Composition for promoting wound healing
CA2810844C (en) * 2010-09-07 2017-03-21 Dmi Acquisition Corp. Diketopiperazine compositions for the treatment of metabolic syndrome and related conditions
US9693936B2 (en) * 2012-03-07 2017-07-04 Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. Dispersions in oil of Dead Sea nano sized material preparation and uses therof
WO2013163423A1 (en) * 2012-04-25 2013-10-31 Musc Foundation For Research Development Compositions and methods for wound healing and tissue repair
WO2015075406A1 (en) 2013-11-19 2015-05-28 Lipopeptide Ab New treatment of chronic ulcers

Also Published As

Publication number Publication date
US20190255147A1 (en) 2019-08-22
ZA201604110B (en) 2020-11-25
MX2016006091A (es) 2016-12-09
MX379357B (es) 2025-03-11
WO2015075406A1 (en) 2015-05-28
AU2014351607A1 (en) 2016-06-23
US10226508B2 (en) 2019-03-12
JP2016537373A (ja) 2016-12-01
BR112016011166A2 (enExample) 2017-08-08
TWI698251B (zh) 2020-07-11
KR20160088914A (ko) 2016-07-26
AU2014351607B2 (en) 2020-03-05
US20200384077A1 (en) 2020-12-10
BR112016011166A8 (pt) 2022-06-28
US10709760B2 (en) 2020-07-14
EP3071216A1 (en) 2016-09-28
ES2925876T3 (es) 2022-10-20
RU2016124234A (ru) 2017-12-25
CN105939726A (zh) 2016-09-14
WO2015075441A1 (en) 2015-05-28
CA2927557A1 (en) 2015-05-28
RU2707254C1 (ru) 2019-11-25
TW201521760A (zh) 2015-06-16
PL3071216T3 (pl) 2022-11-21
EP3071216B1 (en) 2022-08-03
US11191810B2 (en) 2021-12-07
KR102360938B1 (ko) 2022-02-09
US20160271217A1 (en) 2016-09-22
CA2927557C (en) 2023-05-02

Similar Documents

Publication Publication Date Title
US11191810B2 (en) Treatment of chronic ulcers
Jünger et al. Efficacy and tolerability of an ulcer compression stocking for therapy of chronic venous ulcer compared with a below-knee compression bandage: results from a prospective, randomized, multicentre trial
Alvarez et al. Incorporating wound healing strategies to improve palliation (symptom management) in patients with chronic wounds
Humbert et al. Efficacy and safety of a gauze pad containing hyaluronic acid in treatment of leg ulcers of venous or mixed origin: a double‐blind, randomised, controlled trial
RU2014137827A (ru) Композиции и применение противомикробных материалов со свойствами биологической совместимости
JP2015520754A (ja) 創傷治癒のための組合せ治療および組成物
Scalise et al. Enzymatic debridement: is HA-collagenase the right synergy? Randomized double-blind controlled clinical trial in venous leg ulcers.
JP6087917B2 (ja) 病理学的瘢痕の予防および治療のためのオリゴサッカライド化合物の使用
RU2512681C2 (ru) Способ лечения длительно незаживающей раны и/или раневой полости
US11938173B2 (en) Use of Clostridium histolyticum protease mixture in promoting wound healing
Karri et al. Understanding the implications of pharmaceutical excipients and additives in the treatment of diabetic foot ulcers
HK1229249A1 (en) New treatment of chronic ulcers
HK1229249B (en) New treatment of chronic ulcers
Elgayyar et al. Evaluation of chitosan impregnated with silver nanoparticles in the treatment of chronic venous leg ulcer: an open-label controlled study
RU2848912C1 (ru) Способ консервативного этапного лечения трофических язв
CA3192177A1 (en) Compositions and methods for treating wounds
Emadi et al. Efficacy of a novel repairing gel therapy for the management of chronic wounds: a single-center, self-controlled pilot trial
Dini et al. Aetiology, Classification and Advocating for Multidisciplinary Approach
Gopi et al. A prospective study to compare the effectiveness of saline dressing versus povidone iodine dressing in chronic diabetic wound healing: study from a tertiary hospital in south India
Humbert et al. Allaert
CN119997935A (zh) 包含雌四醇组分的局部用组合物及所述组合物用于伤口愈合的用途

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171106

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180705

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180717

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20181010

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181212

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190607

R150 Certificate of patent or registration of utility model

Ref document number: 6539268

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

LAPS Cancellation because of no payment of annual fees